Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients.

Surveyor Capital and Alexandria Venture Investments also participated in the financing. Separately, the California Institute of Regenerative Medicine (CIRM) will provide up to $23 million in grants to aide the development of JSP191, which is intended to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic stem cell transplants...